RE:Ramping up production, very positive signONC has had an approved manufacturing process for more than 20 years.
The last time they gave a significant update during a conference call was back in BT's days when he mentioned something about scaling up from a 20L to 100L bioreactor. At that time they were readying themselves for commercial approval in Head and Neck (see link below). Investors were teased by BT's references to "scaling up manufacturing to near commercial levels." This was so long ago the product was still called Reolysin, before the Pelareorep re-brand which still seems to be adequately explained as an effort to wash away 20+ failed trials.
We all know what happened next. There was no P3 in Head and Neck and fifteen years later we are still awaiting the start of a P3 in any indication.
All investors in ONC have known for more than 15 years that manufacturing of Pelareorep can be scaled to commercial levels. There is no sensible reason why they would devote so much time during the last convference call to the mundane issue of manufacturing.
This can only lead to speculation, and I can come up with only two scenarios:
1. ONC is on the verge of being approved for marketing Pelareorep based on the amazing P2 data in Panc. (I present this as a less than 1% possibility, but it does exist).
2. ONC is playing the same game they did back in 2009. (see below)
https://www.newswire.ca/news-releases/oncolytics-biotechr-inc-announces-2009-year-end-results-539575792.html